<DOC>
	<DOCNO>NCT01758198</DOCNO>
	<brief_summary>The purpose study compare clinical efficacy include joint damage progression safety Abatacept plus Methotrexate ( MTX ) placebo plus MTX .</brief_summary>
	<brief_title>Abatacept Post-marketing Clinical Study Japan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>MTX inadequate responder Biologic Naïve Functional class I , II III ≥6 swell ≥6 tender joint Creactive protein ( CRP ) ≥2.0mg/dl erythrocyte sedimentation rate ( ESR ) ≥28 mm/hr Anticyclic citrullinated peptide ( CCP ) antibody positive Have erosion Any rheumatic disease Active angiitis main organ exclude rheumatoid nodule</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>